Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines \textit{in vitro}, and is attenuated and induces protective immunity in calves

Geraldine Taylor,\(^1\) Sara Wyld,\(^1\) Jean-Francois Valarcher,\(^1\) Efrain Guzman,\(^1\) Michelle Thom,\(^1\) Stephanie Widdison\(^1\) \& Ursula J. Buchholz\(^2\)

\(^1\)Pirbright Institute, Woking, Surrey, GU24 0NF, UK
\(^2\)Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA

Bovine respiratory syncytial virus (BRSV) causes inflammation and obstruction of the small airways, leading to severe respiratory disease in young calves. The virus is closely related to human (H)RSV, a major cause of bronchiolitis and pneumonia in young children. The ability to manipulate the genome of RSV has provided opportunities for the development of stable, live attenuated RSV vaccines. The role of the SH protein in the pathogenesis of BRSV was evaluated in vitro and in vivo using a recombinant (r)BRSV in which the SH gene had been deleted. Infection of bovine epithelial cells and monocytes with rBRSV\(^{-}\)SH, \textit{in vitro}, resulted in an increase in apoptosis, and higher levels of TNF-\(\alpha\) and IL-1\(\beta\) compared with cells infected with parental, wild-type (WT) rBRSV. Although replication of rBRSV\(^{-}\)SH and WT rBRSV, \textit{in vitro}, were similar, the replication of rBRSV\(^{-}\)SH was moderately reduced in the lower, but not the upper, respiratory tract of experimentally infected calves. Despite the greater ability of rBRSV\(^{-}\)SH to induce pro-inflammatory cytokines, \textit{in vitro}, the pulmonary inflammatory response in rBRSV\(^{-}\)SH-infected calves was significantly reduced compared with that in calves inoculated with WT rBRSV, 6 days previously. Virus lacking SH appeared to be as immunogenic and effective in inducing resistance to virulent virus challenge, 6 months later, as the parental rBRSV. These findings suggest that rBRSV\(^{-}\)SH may be an ideal live attenuated virus vaccine candidate, combining safety with a high level of immunogenicity.
of that seen in babies vaccinated with formalin-inactivated HRSV (Kim et al., 1969). The ability to manipulate the genome of RSVs has allowed analysis of the role of viral proteins in the pathogenesis of disease and has provided opportunities for the development of stable, live attenuated virus vaccines. However, a problem with this approach has been that attenuation is usually based on decreased virus replication, which is associated with reduced immunogenicity. Although an effective HRSV vaccine is not yet available, one promising candidate is a temperature-sensitive mutant virus that also lacks the SH gene, rA2cp248/404/1030/ΔSH. Following intranasal (i.n.) vaccination of 1- to 2-month-old infants, this virus was well tolerated and immunogenic, and protected against a second dose of the same vaccine given 4 to 8 weeks after the first dose (Karron et al., 2005).

The SH protein, which is a short type II integral membrane glycoprotein, is not essential for virus replication in cell culture. However, HRSV lacking the SH gene (rHRSVΔSH) exhibited different patterns of site-specific attenuation in the respiratory tract of mice and chimpanzees. Thus, replication of rHRSVΔSH was attenuated only in the upper respiratory tract of mice (Bukreyev et al., 1997), and only in the lower respiratory tract of chimpanzees (Whitehead et al., 1999). Nevertheless, chimpanzees infected with rHRSVΔSH developed less rhinorrhea than those infected with WT HRSV. The reasons for differences in the site-specific attenuation of rHRSVΔSH in mice and chimpanzees are not clear. Studies of rHRSVΔSH in cell culture suggest that, similar to other paramyxoviruses, the SH protein inhibits apoptosis and TNF-α signalling (Fuentes et al., 2007; Lin et al., 2003). The HRSV SH protein forms pentameric and hexameric complexes in membranes, altering membrane permeability, and the transmembrane domain of SH has been shown to act as an ion channel in synthetic membranes (Carter et al., 2010; Gan et al., 2012; Perez et al., 1997). Transmembrane pore-forming viral proteins that form ion channels (viroporins), such as influenza virus M2 and encephalomyocarditis virus 2B, play a central role in activation of the NLRP3 inflammasome pathway resulting in secretion of IL-1β and IL-18 (Ichinohe et al., 2010; Ito et al., 2012). There is evidence that HRSV also activates the NLRP3 inflammasome, inducing secretion of IL-1β (Segovia et al., 2012; Triantafilou et al., 2013).

IL-1β and IL-18 play an important role in inflammation by orchestrating the pro-inflammatory response, and are important regulators of innate and adaptive immune responses. These cytokines are produced as cytosolic precursors that require proteolytic cleavage induced by the inflammasome for activation and secretion. BRSV and HRSV induce the production of pro-inflammatory cytokines, including IL-β, in vivo and in vitro (Bermejo-Martin et al., 2007; Fach et al., 2010; Werling et al., 2002). Activation of the NLRP3/ASC inflammasome by HRSV in mouse bone marrow macrophages is initiated by Toll-like receptor-2 (TLR-2)/Myd88/NF-κB signalling (signal 1), and reactive oxygen species (ROS) and K+ ion efflux (signal 2) (Segovia et al., 2012). In contrast, studies in human lung epithelial cells indicated that activation of the NLRP3/ASC inflammasome by HRSV was initiated by TLR-4 (signal 1) and involved the SH protein of RSV (signal 2) (Triantafilou et al., 2013). Thus, rHRSVΔSH failed to induce IL-1β secretion from primary human epithelial lung cells.

Activation of the inflammasome and production of IL-1β is responsible for neutrophil recruitment and inflammation in the lungs of mice infected with influenza virus (Ichinohe et al., 2009; Schmitz et al., 2005; Thomas et al., 2009). The demonstration that rHRSVΔSH failed to induce IL-1β secretion in airway epithelial cells (Triantafilou et al., 2013) may explain, at least in part, the reduced rhinorrhea seen in chimpanzees infected with rHRSVΔSH (Whitehead et al., 1999). However, activation of the inflammasome plays an important role in orchestrating the innate and adaptive immune response, and mice deficient in components of the inflammasome pathway or which lack IL-18 receptors are more susceptible to influenza virus infection than wild-type mice and have reduced T-cell and antibody responses (Ichinohe et al., 2009; Schmitz et al., 2005). These observations suggest that failure to induce IL-1β by rHRSVΔSH may have a negative impact on priming of a protective immune response, and consequently, deletion of SH would be expected to enhance virus replication in the respiratory tract, rather than attenuate replication as has been observed in mice and chimpanzees.

In order to understand the role of the SH protein in induction of IL-1β and the pathogenesis of RSV, we analysed the effects of deletion of the SH gene on the induction of pro-inflammatory cytokines and apoptosis in vitro and on the pathogenesis of BRSV in calves, a natural host of the virus. In addition, the ability of mucosal immunization with rBRSVΔSH to induce a protective immune response was evaluated.

RESULTS

Induction of apoptosis by rBRSV lacking the SH gene

Compared with parental rHRSV, rHRSV lacking SH produces larger plaques and grows to slightly higher titres in some, but not other cell lines (Bukreyev et al., 1997), and induces significantly more apoptosis than parental rHRSV in L929 and A549 cells (Fuentes et al., 2007). Although we found that there was little or no difference either in the plaque size of parental, WT rBRSV and rBRSVΔSH in Vero cells (data not shown), or in the replication of rBRSVΔSH and WT rBRSV in either primary calf testes or MDBK cells (Fig. 1), a cytopathic effect was seen earlier in MDBK cells infected with rBRSVΔSH than in cells infected with WT rBRSV. Infection of MDBK cells or bovine monocytes (CD14+ cells) with rBRSVΔSH induced significantly more apoptosis than WT rBRSV, 48 h or 24 h after infection, respectively (P<0.0001, P<0.01) (Fig. 2a, b). Apoptosis of bovine monocytes 24 h after infection was only seen at an

http://vir.sgmjournals.org
m.o.i. of 3 and there was little or no apoptosis at an m.o.i. of 1 (Fig. 2b).

**Induction of pro-inflammatory cytokines**

Previous studies have shown that the SH protein of paramyxoviruses plays an important role in inhibiting induction of TNF-α (Fuentes et al., 2007; Lin et al., 2003). We therefore analysed the effect of infection with rBRSVΔSH on the level of TNF-α in the supernatant from bovine monocytes. Although neither WT virus nor rBRSVΔSH replicated in bovine monocytes, cells infected with rBRSVΔSH produced significantly greater amounts of TNF-α than those infected with the parental WT rBRSV (Fig. 3a). Similarly, the level of IL-1β in supernatants from bovine monocytes and MDBK cells infected with rBRSVΔSH was significantly greater than that from cells infected with WT rBRSV (Fig. 3b, c).

**The SH-deleted mutant of BRSV is attenuated in the lower respiratory tract of calves**

Since previous studies have shown that there are differences in the site-specific attenuation of rHRSVΔSH in mice and chimpanzees, we compared the replication of WT rBRSV and rBRSVΔSH in the respiratory tract of gnotobiotic calves following i.n. and intratracheal (i.t.) inoculation. Replication of WT and ΔSH rBRSV in the nasopharynx of calves was not significantly different, at least up to 6 days post-infection (p.i.) (Fig. 4a). In contrast, replication of rBRSVΔSH in the lower respiratory tract was attenuated compared with that of WT rBRSV (Fig. 4b). Thus, levels of virus were significantly (P<0.01) higher in lung homogenates from calves infected with the WT virus than from those infected with the ΔSH mutant, for samples taken from all lobes. Furthermore, the titre of rBRSVΔSH in bronchial lavage (BAL) cells was 10-fold less than that of...
WT rBRSV, although the difference was not statistically significant.

None of the calves developed clinical signs of respiratory disease. However, in contrast to calves infected with WT rBRSV, calves infected with rBRSV\textsuperscript{DSH} developed little or no macroscopic pneumonia (Fig. 5a). Furthermore, the total number of cells in BAL from calves infected with rBRSV\textsuperscript{DSH} was twofold less than that from calves infected with WT rBRSV, and the numbers of neutrophils in BAL were significantly reduced (Fig. 5b). Microscopic lung lesions in calves infected with WT rBRSV were similar to those described previously (Thomas\textit{ et al.}, 1984) and were characterized by a proliferative and exudative bronchiolitis, a peribronchiolar accumulation of lymphocytes and alveolitis. Microscopic lung lesions in calves infected with rBRSV\textsuperscript{DSH} were similar but much less extensive. Numerous apoptotic cells can be seen in vacuoles in bronchial epithelial cells of BRSV-infected calves (Viuff\textit{ et al.}, 2002). Since rBRSV\textsuperscript{DSH} infection increased apoptosis, \textit{in vitro}, we analysed sections of trachea and lung from calves infected with either WT rBRSV or rBRSV\textsuperscript{DSH}, but not in airway epithelium from mock-infected calves (Fig. 6). Although microscopic changes were not very extensive in calves infected with rBRSV\textsuperscript{DSH}, there did not appear to be any major differences in the numbers of vacuoles containing cell debris in areas of lung sections

\textbf{Fig. 3.} BRSV lacking the SH gene induces secretion of high levels of TNF-\textgreek{z} and IL-1/\textgreek{b}. Bovine monocytes were infected with WT rBRSV or rBRSV lacking the SH gene (\textgreek{A}SH) at an m.o.i. of 1 (a, b); and MDBK cells were infected with WT or \textgreek{A}SH rBRSV at an m.o.i. of 3 (c). As controls, cells were exposed to mock-infected tissue culture cell lysate (Con). At 24 h post-infection, levels of TNF-\textgreek{z} (a) and IL-1/\textgreek{b} (b, c) in the supernatant were determined by ELISA. Results are expressed as the mean±SD of triplicate samples. *, WT rBRSV induced significantly higher levels of TNF-\textgreek{z} or IL-1/\textgreek{b} than controls, P<0.03; **, rBRSV\textsuperscript{A}SH induced significantly higher levels of TNF-\textgreek{z} or IL-1/\textgreek{b} than WT rBRSV, P<0.0001.

\textbf{Fig. 4.} Replication of SH deletion mutant of BRSV in the respiratory tract of calves. Two-to-three-week-old gnotobiotic calves were inoculated i.n. and i.t. with 5\times10^6 p.f.u. WT rBRSV (n=4) or rBRSV lacking the SH gene (\textgreek{A}SH) (n=3). (a) Nasopharyngeal excretion of virus expressed as the mean log\textsubscript{10}(p.f.u. ml\textsuperscript{-1})±SD. (b) Mean titre of virus [log\textsubscript{10}(p.f.u.)±SD] in BAL cells, or homogenates of samples from the right apical (RA), right cardiac (RC) and left cardiac (LC) lobes of the lung, 6 days after infection.
showing inflammation when compared with sections from calves infected with WT rBRSV.

**Mucosal immunization with rBRSV lacking SH protects against challenge with virulent BRSV**

In order to determine the ability of mucosal immunization with rBRSVΔSH to induce a protective immune response, groups of four or five colostrum-restricted calves that had been inoculated i.n. and i.t. with WT rBRSV, rBRSVΔSH or control Vero cell lysate, 6 months previously, were challenged with the Snook strain of BRSV. As seen previously in gnotobiotic calves, there was no difference in the replication of WT and ΔSH rBRS viruses in the nasopharynx, and virus was cleared by day 8 in both groups of infected animals. Furthermore, none of the calves developed clinical signs of respiratory disease. Although calves infected with WT rBRSV had higher levels of maternally derived BRSV-specific serum antibodies at the time of mucosal immunization than calves infected with rBRSVΔSH, the serum IgG antibody response, as determined by ELISA, and the neutralizing antibody response induced by rBRSV and rBRSVΔSH were not statistically significantly different (Fig. 7a, c). Infection with WT or ΔSH rBRSV also induced BRSV-specific IgA in nasal secretions. Mucosal IgA reached a peak at 2 weeks after vaccination in both groups of calves and the titres were not significantly different (Fig. 7b). After a peak between 4 and 8 weeks after immunization, levels of BRSV-specific serum IgG and neutralizing antibodies declined slowly over the 6 months. In contrast, mock-infected control calves did not develop a BRSV-specific serum or mucosal antibody response (results not shown).

Following challenge with virulent BRSV, clinical signs of respiratory disease were seen 5 to 6 days after challenge in two out of four control calves, one out of four calves immunized with rBRSVΔSH and none of the calves immunized with WT rBRSV. At post-mortem examination, 6 days after BRSV challenge, macroscopic lung lesions of >5% of the lung were observed in three out of four control calves (Fig. 8a). In contrast, there was little or no pneumonic consolidation in calves immunized with either WT rBRSV or rBRSVΔSH (Fig. 8a). Following challenge, virus was not isolated from the nasopharynx or lung tissue of any of the immunized calves but was isolated from the nasopharynx (Fig. 8b) and lung tissue of three of the four control calves (results not shown). Similarly, virus was not isolated, or only detected in low titres, in BAL cells from calves immunized with rBRSVΔSH or WT rBRSV, but was isolated in high titres from control calves (Fig. 8b).
Fig. 7. BRSV-specific antibody responses induced by mucosal vaccination of calves with rBRSV. Calves were inoculated i.n. and i.t. with 5×10⁶ p.f.u. WT rBRSV (n=5) or rBRSV lacking the SH gene (ΔSH) (n=4). Calves were challenged 24 weeks after vaccination with 1×10⁴ p.f.u. of the Snook strain of BRSV in BAL. BRSV-specific IgG antibody responses in sera (a) and BRSV-specific IgA antibody in nasal secretions, 2 weeks after vaccination (b) were determined by ELISA. (c) BRSV-specific serum neutralizing antibody responses were determined by a plaque reduction assay. Results are expressed as the geometric mean titre (log₁₀) ± SD.

Fig. 8. Recombinant BRSV lacking SH protects against challenge with virulent BRSV. Calves were inoculated i.n. and i.t. with 5×10⁶ p.f.u. WT rBRSV (n=5) or rBRSV lacking the SH gene (ΔSH) (n=4). As controls, calves were inoculated i.n. and i.t. with control tissue culture cell lysate. Calves were challenged 24 weeks after vaccination with 1×10⁴ p.f.u. of the Snook strain of BRSV in BAL and killed 6 days after challenge. (a) Percentage of the lung showing macroscopic lung lesions, 6 days after challenge. (b) Peak virus titres in the nasopharynx (solid symbols) and titre of virus in BAL cells, 6 days after challenge (open symbols).
DISCUSSION

In this study, we demonstrated that although BRSV lacking the SH gene replicated as efficiently as WT rBRSV in tissue culture cells, the mutant virus exhibited site-specific attenuation in the bovine respiratory tract, and was as effective as WT rBRSV in inducing resistance to challenge with virulent BRSV, 6 months after vaccination. Although previous studies have shown that the final titre challenge with virulent BRSV, 6 months after vaccination, was as effective as WT rBRSV in inducing resistance to specific attenuation in the bovine respiratory tract, and lacking the SH gene replicated as efficiently as WT rBRSV. Therefore, the greater level of apoptosis seen in rBRSV compared with that of parental rBRSV (Karger et al., 2001), we could not detect any differences in the replication of rBRSVASH and parental WT rBRSV in either calf tests or MDBC cells. Studies with rHRSV lacking the SH gene (D46/ 6368) showed that the mutant virus formed larger plaques on Hep-2 cells, and replicated to higher titres than parental rHRSV in some, but not all, cell lines tested (Bukreyev et al., 1997). Therefore, differences in the replication of rBRSVASH, in vitro, may be related to the use of different cell lines, or to differences in cell lines maintained in different laboratories. Taken together, studies on rHRSV and rBRSV lacking the SH protein demonstrate that SH is not essential for virus replication, in vitro. In contrast, the replication of rBRSVASH was attenuated in the lungs of calves. Thus, the site-specific attenuation of rBRSVASH in calves resembled that of rHRSVASH in chimpanzees (Whitehead et al., 1999).

Although the parental WT rBRSV did not induce clinical signs of disease, it induced an extensive pulmonary inflammatory response and gross pneumatic lesions. Attempts to induce clinical signs of respiratory disease in calves experimentally infected with BRSV have yielded inconsistent results. However, non- or low-cell-culture-passaged virus can induce disease similar to that seen in naturally occurring outbreaks (van der Poel et al., 1996). In the field, other factors such as secondary infections, adverse environmental temperatures or housing may contribute to the severity of disease. Nevertheless, the marked reduction in lung pathology seen in calves infected with rBRSVASH compared with that induced by WT rBRSV suggests that SH plays a role in RSV pathogenesis.

HRSV and BRSV do not usually induce apoptosis until the late stages of infection (Cristina et al., 2001; Ketelkin et al., 2003). However, rBRSVASH resembled rHRSVASH in inducing significantly more apoptosis than WT virus, in vitro (Fuentes et al., 2007). Studies with rPIV5ASH have suggested that the SH protein inhibits TNF-α-induced apoptosis (Lin et al., 2003). Like rPIV5ASH, we found that rBRSVASH-infected bovine monocytes produced significantly greater amounts of TNF-α than cells infected with WT rBRSV. Therefore, the greater level of apoptosis seen in rBRSVASH-infected cells compared with cells infected with WT rBRSV may be mediated by the higher levels of TNF-α induced in rBRSVASH-infected cells. However, apoptosis of bovine monocytes, 24 h after infection with rBRSVASH at an m.o.i. of 1, was low at a time when high levels of TNF-α were present in the supernatant.

Apoptosis is an important early host defence that limits virus replication and spread, and many viruses have developed strategies to inhibit apoptosis, thereby prolonging their ability to replicate. An early onset of apoptosis following virus infection may help to control virus replication, as seen for rPIV5ASH, which induced increased apoptosis, in vitro, and was attenued in vivo (He et al., 2001). The observation that a large number of apoptotic cells containing BRSV antigen can be seen in vacuoles in the bronchial epithelium of calves infected 6 days previously with BRSV has led to the suggestion that apoptosis is an important pathway of virus clearance in BRSV-infected calves (Viuff et al., 2002). Therefore, an accelerated or increased induction of apoptosis by rBRSVASH may explain its restricted replication in the lungs. However, this does not explain the similar level of replication and rate of clearance of rBRSVASH and WT rBRSV seen in the nasopharynx. It is possible that the higher pro-apoptotic potential of rBRSVASH could predispose the airways to secondary bacterial infections. However, we found no evidence for this, and, furthermore, we could not detect any major differences in the number of vacuoles containing cell debris in ciliated airway epithelium in calves infected 6 days previously with rBRSVASH or WT rBRSV.

An alternative explanation for the site-specific attenuation of rBRSVASH may be related to induction of TNF-α by monocytes and macrophages, which are more prevalent in the lower respiratory tract than in the nasopharynx. Although TNF-α is a major mediator of RSV-associated illness in BALB/c mice, it is important in clearance of virus-infected cells during the early stages of infection (Rutigliano & Graham, 2004).

The observation that rBRSVASH induced significantly higher levels of IL-1β than WT rBRSV in MDBK cells and bovine monocytes contrasts with that of Triantafilou et al. (2013), who found that rHRSVASH did not induce secretion of IL-1β in primary human lung epithelial cells. The reasons for this discrepancy are not clear. One possibility is that, since there is only 38% amino acid identity between the SH proteins of BRSV and HRSV, they may have different functions. However, the close relationship between HRSV and BRSV makes this unlikely. The predicted hydropathy profiles of BRSV and HRSV SH proteins are similar (Samal & Zamora, 1991) and, of the amino acids (His22, and either His51 or Trp15) that have been implicated in HRSV SH ion channel activity (Carter et al., 2010; Gan et al., 2012), Trp15 and His51 are conserved in the BRSV SH protein. Since activation of the inflamasome by HRSV is mediated by different signals in different cells (Segovia et al., 2012; Triantafilou et al., 2013), it is possible that differences in induction of IL-1β by rHRSVASH and rBRSVASH may be related to the type of cells that were infected. However, rBRSVASH induced higher levels of IL-1β than WT rBRSV in both bovine epithelial (MDBK) cells and bovine monocytes. Alternatively, differences in the response to infection with ASH RS viruses may be related to differences in their construction resulting in differing levels of read-through transcripts, and consequently, the level of expression of
downstream viral genes. Thus, differences in the intergenic regions, or expression of an additional gene such as GFP, as in the rHRSVΔSH used in studies by Triantafilou et al. (2013), may have affected the gradient of transcription and the level of expression of, for example, the G and F proteins. The G protein of HRSV inhibits IL-6 and IL-1β production in human monocytes (Polack et al., 2005). Therefore, differences in the level of G protein produced by ASH viruses may influence induction of IL-1β. There are high levels of read-through mRNAs of the M gene and the respective downstream genes in rHRSV (D46/6368) (Bukreyev et al., 1997) and rBRSVΔSH (Karger et al., 2001). However, this does not appear to translate to corresponding higher levels of downstream proteins in cells infected with rHRSV (D46/6368). Other studies have shown that TNF-α can induce caspase-1 activation and IL-1β secretion (Dinarello et al., 1986; Franchi et al., 2009). Therefore, it is possible that increased secretion of IL-1β by cells infected with rBRSVΔSH was mediated by TNF-α.

Studies in mice infected with influenza virus have demonstrated that IL-1β is responsible for neutrophil recruitment and inflammation in the lungs (Ichinohe et al., 2009; Schmitz et al., 2005; Thomas et al., 2009). Increased secretion of IL-1β by bovine monocytes infected with rBRSVΔSH might be expected to result in increased inflammation in the lungs of calves infected with this virus. However, the pulmonary inflammatory response in calves infected with rBRSVΔSH was reduced in comparison with that seen in calves infected with WT rBRSV 6 days previously. Early induction of IL-1β and TNF-α by rBRSVΔSH in the lungs may have contributed to rapid control of virus replication and, therefore, less inflammation, 6 days after infection. Further studies to compare innate immune responses in the lungs of calves infected with rBRSVΔSH or WT rBRSV are required to understand the mechanisms responsible for the reduced virus replication and reduced pulmonary inflammatory response in calves infected with rBRSVΔSH.

Despite the attenuation of rBRSVΔSH in the lower respiratory tract of calves, BRSV-specific antibody responses induced by the mutant virus were similar to those induced by WT rBRSV. Furthermore, infection with rBRSVΔSH was as effective as that with WT rBRSV in protecting against BRSV challenge 6 months later. The observation that attenuation of rBRSVΔSH did not appear to be associated with reduced immunogenicity may be related to increased activation of components of the innate immune response, such as apoptosis and IL-1β. Apoptosis enhances antigen presentation, and apoptotic cells or bodies are major sources for antigen cross-presentation. An increase in apoptosis by a recombinant rabies virus overexpressing cytochrome c resulted in attenuation of pathogenicity and enhanced immunity (Pulmanausahakul et al., 2001). Similarly, the enhanced immune response and greater vaccine efficacy against influenza virus induced in mice by rPIV5ΔSH expressing influenza haemagglutinin was associated with increased apoptosis, in vitro, and attenuation of virus replication, in vivo (Li et al., 2013). Activation of the inflammasome and induction of IL-1β and IL-18 secretion also appear to be important for induction of adaptive immunity. Thus, priming of influenza virus-specific T cells, and levels of nasal IgA were significantly reduced in mice deficient in ASC, caspase-1 or IL-1R (Ichinohe et al., 2009); and deletion of the gene encoding the viral IL-1β receptor in modified vaccinia virus Ankara enhanced the induction of memory CD8 T cells (Staib et al., 2005). However, other studies have failed to demonstrate a role for caspase-1 in induction of the adaptive immune response to influenza virus (Thomas et al., 2009).

In conclusion, rBRSVΔSH showed site-specific attenuation in the respiratory tract of calves, and was as immunogenic and effective as WT rBRSV in inducing resistance to challenge with virulent BRSV. These properties may be related to an increased induction of components of the innate immune response, such as apoptosis and IL-1β, in rBRSVΔSH-infected cells. In contrast to a biologically derived vaccine candidate attenuated by point mutations, rBRSVΔSH containing the deletion of an entire gene should be highly refractory to reversion to virulence. Furthermore, the probability of regaining the deleted gene by recombination is likely to be a very rare event (Spann et al., 2003). As the fusion glycoprotein, which is the major protective antigen, is highly conserved between BRSV isolates (Valarcher et al., 2000), immune responses induced by SH-deleted BRSV are likely to be broadly protective in the field. Therefore, rBRSVΔSH appears to be an ideal vaccine candidate, combining safety with a high level of immunogenicity.

**METHODS**

**Viruses and cells.** WT recombinant (r)BRSV and virus lacking the SH gene (∆SH) were derived from full-length cDNA of BRSV strain A51908, variant Atue51908 (GenBank accession no. AF092942) (Karger et al., 2001). Stocks of rBRSV were prepared in Vero cell monolayers, infected at an m.o.i. between 0.1 and 0.5, in Dulbecco’s modified Eagle’s medium (DMEM; Gibco-BRL) containing 2% heat-inactivated fetal calf serum (FCS). All recombinant virus stocks were free from contamination with bovine viral diarrhea virus (BVDV) and mycoplasmas. Virulent BRSV consisted of BAL prepared from a gnotobiotic calf, inoculated 6 days previously with the Snook strain of BRSV, which is closely related to BRSV Atue51908 (Valarcher et al., 2003). The BAL was free from other viruses, mycoplasmas and bacteria as assessed by inoculation of tissue culture cells, or mycoplasmal or bacterial media. Replication of rBRSV and rBRSVΔSH in primary calf testes cells and MDBK cells, infected at an m.o.i. of 0.1 and incubated at 37 °C or 6 days, was determined as described previously (Valarcher et al., 2003). Virus titres were determined by plaque assay on fetal calf kidney (FCK) or Vero cell monolayers in 35 mm Petri dishes (Thomas et al., 1982).

**Calves and experimental design.** Gnotobiotic, BRSV-seronegative calves were derived, reared and maintained individually in plastic isolators as described previously (Dennis et al., 1976). To evaluate the virulence of rBRSV, groups of three or four gnotobiotic calves were infected at 2 to 3 weeks of age with approximately 10⁸ p.f.u. virus in a volume of 10 ml administered i.n. and 10 ml i.t. A clinical examination was performed twice a day following virus infection, and...
nasopharyngeal swabs were obtained daily to monitor virus excretion from the nasopharynx. Calves were killed 6 days after infection, by intravenous injection of sodium pentobarbital. At post-mortem examination, macroscopic lung lesions were recorded on a standard lung diagram, and the extent of pneumonia/consolidation was expressed as a percentage of the lung area. BAL was collected by irrigating the lungs from each calf with 300 ml PBS (Taylor et al., 1995). Cytocentrifuge preparations of BAL cells were fixed in neutral buffered formalin and stained with haematoxylin and eosin. Differential counts of 300 to 350 cells per slide were made using oil immersion. Cells prepared from 0.1 ml BAL by centrifugation at 1200 g for 15 min at 4 °C were resuspended in 5 ml of lung buffer for analysis of virus titre (Taylor et al., 1995). Three pieces of pneumonia lung taken from different lobes were homogenized in lung buffer to give a 20% (w/v) suspension. Titres of rBRSV in nasopharyngeal swabs, BAL cells and lung homogenates were determined by plaque assay on Vero cells.

The ability of rBRSVASH to induce protective immunity was determined in three groups of colostro-restricted calves, produced by collecting them at birth and artificially feeding them with 500 ml of colostrum that contained low levels of BRV-specific antibodies. Calves were inoculated i.n. and i.t. at 1 to 4 weeks of age, with 10^4 p.f.u. WT rBRSV, rBRSVASH or a lysate of non-infected Vero cells. Nasopharyngeal swabs were obtained daily for 10 days to monitor virus excretion from the nasopharynx. Blood was obtained at intervals for analysis of BRV-specific antibodies. Six months after vaccination, calves were challenged i.n. and i.t. with 10^6 p.f.u. WT rBRSV, rBRSVASH or a lysate of non-infected Vero cells. Nasopharyngeal swabs were obtained daily for 10 days after challenge to determine the extent of gross pneumatic lesions and the titre of virus in BAL cells.

All calf experiments were performed under the regulations of the Home Office Scientific Procedures Act (1986) of the UK. The studies have been approved by the Pirbright Institute Animal Welfare & Ethical Review Body.

**Serology.** BRV-specific antibodies in sera were analysed by ELISA using a lysate of BRV (Snook)-infected FCK cells as antigen and mock-infected FCK cells as control antigen (Taylor et al., 1995). Neutralizing antibodies were determined by a plaque reduction assay on Vero cells using the Snook strain of BRV and heat-inactivated (56 °C for 30 min) sera (Kennedy et al., 1988).

**Histology.** A tracheal ring taken from approximately 5 cm below the larynx and pieces of lung from each of three different lobes were fixed in 10% neutral buffered formalin and embedded in paraffin wax, and sections were stained with haematoxylin and eosin.

**Induction of pro-inflammatory cytokines and apoptosis, in vitro.** Bovine monocytes were prepared from heparinized venous blood by centrifugation at 1200 g over Histopaque 1086 (Sigma). The peripheral blood mononuclear cells were washed three times with PBS and CD14+ cells were purified by magnetic antibody cell sorting using anti-human CD14+ microbeads (Miltenyi Biotec) (Sopp & Howard, 1997), following the manufacturer’s instructions. CD14+ cells in RPMI medium with 3% FCS, ampicillin (0.1 µg ml⁻¹) and 5 x 10⁻³ M 2-mercaptoethanol and MDBK cells in Eagle’s MEM containing 2% FCS, 1% non-essential amino acids, 100 U penicillin ml⁻¹, and 100 µg streptomycin ml⁻¹ were infected with WT BRV or BRVASH at an m.o.i. of 1 or 3. Virus was adsorbed for 1.5 h at 37 °C in 5% CO₂/air. After adsorption, the cells were washed twice with PBS, fresh medium was added and cells were incubated at 37 °C in 5% CO₂/air. As a control, cells were treated with mock-infected Vero cells lysate for 1.5 h. At 24 h post-infection, supernatants were collected and levels of IL-1β were analysed using a bovine IL-1β ELISA kit (Pierce Protein Biology Products), and levels of TNF-α were analysed by ELISA as described previously (Kwong et al., 2010). At 24 h post-infection, bovine monocytes were removed from tissue culture wells using cell-dissociation fluid solution (Sigma-Aldrich), and MDBK cells were removed at 24 h and 48 h p.i. by treatment with trypsin and EDTA. Terminal deoxynucleotidyltransferase dUTP nick end labelling (TUNEL) was performed using the APO-BRDU kit (AbD Serotec), according to the manufacturer’s instructions, to detect apoptotic cells by dual colour flow cytometry.

**Statistics.** Data were analysed for statistical significance using either ANOVA or a two-sample t-test. P values less than 0.05 were considered statistically significant. Viral levels in lung homogenates of calves were analysed using a linear mixed model with log_{10}(p.f.u. g⁻¹) as the response variable, virus (WT or ΔASH) and lobe (RA, RC or LC) as fixed effects and calf as a random effect. Model selection proceeded by stepwise deletion of non-significant terms (as judged by the Akaike information criterion), starting from a model including virus, lobe and an interaction between them. Once a final model had been constructed, differences between factors were explored using Tukey’s honest significant differences (which corrects for multiple testing). All analyses were implemented in R (R Core Team 2013) (http://www.R-project.org/).

**ACKNOWLEDGEMENTS**

This work was supported by the European Commission (EC 5th FP-RSV Vac QLK2-CT-1999-00443), the Department for Environment, Food and Rural Affairs, UK and the BBSRC Institute Strategic Programme on Livestock Viral Diseases at the Pirbright Institute. U. J. B. was supported by the Intramural Research Program of the NIH, NIAID. We thank Animal Services at the Pirbright Institute for all their help and Dr Simon Gubbins, Pirbright Institute, for statistical advice.

**REFERENCES**

Bermejo-Martin, J. F., Garcia-Arevalo, M. C., Alonso, A., De Lejarazu, R. O., Pino, M., Resino, S., Tenorio, A., Bernardo, D., Leon, A. J. & other authors (2007). Persistence of proinflammatory response after severe respiratory syncytial virus disease in children. *J Allergy Clin Immunol* 119, 1547–1550.

Bukreyev, A., Whitehead, S. S., Murphy, B. R. & Collins, P. L. (1997). Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. *J Virol* 71, 8973–8982.

Carter, S. D., Dent, K. C., Atkins, E., Foster, T. L., Verow, M., Gorny, P., Harris, M., Hiscox, J. A., Ranson, N. A. & other authors (2010). Direct visualization of the small hydrophobic protein of human respiratory syncytial virus reveals the structural basis for membrane permeability. *FEBS Lett* 584, 2786–2790.

Cristina, J., Yunus, A. S., Rockemann, D. D. & Samal, S. K. (2001). Bovine respiratory syncytial virus can induce apoptosis in MDBK cultured cells. *Vet Microbiol* 83, 317–320.

Dennis, M. J., Davies, D. C. & Hoare, M. N. (1976). A simplified apparatus for the microbiological isolation of calves. *Br Vet J* 132, 642–646.

Dinarello, C. A., Cannon, J. G., Wolff, S. M., Bernheim, H. A., Beutler, B., Cerami, A., Figari, I. S., Palladino, M. A., Jr & O’Connor, J. V. (1976). Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. *J Exp Med* 143, 1433–1450.

Fach, S. J., Olivier, A., Gallup, J. M., Waters, T. E., Ackermann, M. R., Lehmkhuli, H. D. & Sacco, R. E. (2010). Differential expression of
cytokine transcripts in neonatal and adult ovine alveolar macrophages in response to respiratory syncytial virus or Toll-like receptor ligation. *Vet Immunol Immunopathol* 136, 55–64.

Franchi, L.,Eigenbrad, T. & Núñez, G. (2009). Cutting edge: TNF-α mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. *J Immunol* 183, 792–796.

Fuentes, S., Tran, K. C., Luthra, P., Teng, M. N. & He, B. (2007). Function of the respiratory syncytial virus small hydrophobic protein. *J Virol* 81, 8361–8366.

Gan, S. W., Tan, E., Lin, X., Yu, D., Wang, J., Tan, G. M., Vararattanavech, A., Yeo, C. Y., Soon, C. H. & other authors (2012). The small hydrophobic protein of the human respiratory syncytial virus forms pentameric ion channels. *J Biol Chem* 287, 24671–24689.

He, B., Lin, G. Y., Durbin, J. E., Durbin, R. K. & Lamb, R. A. (2001). The SH integral membrane protein of the paramyxovirus simian virus 5 is required to block apoptosis in MDBK cells. *J Virol* 75, 4068–4079.

Ichinohe, T., Lee, H. K., Ogura, Y., Flavell, R. & Iwasaki, A. (2009). Inflammasome recognition of influenza virus is essential for adaptive immune responses. *J Exp Med* 206, 79–87.

Ichinohe, T., Pang, I. K. & Iwasaki, A. (2010). Influenza virus activates inflammasomes via its intracellular M2 ion channel. *Nat Immunol* 11, 404–410.

Ito, M., Yanagi, Y. & Ichinohe, T. (2012). Encephalomyocarditis virus viroporin 2B activates NLRP3 inflammasome. *PLoS Pathog* 8, e1002857.

Johnson, J. E., Gonzalez, R. A., Olson, S. J., Wright, P. F. & Graham, B. S. (2007). The histopathology of fatal untreated human respiratory syncytial virus infection. *Mod Pathol* 20, 108–119.

Karger, A., Schmidt, U. & Buchholz, U. J. (2001). Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin. *J Gen Virol* 82, 631–640.

Karron, R. A., Wright, P. F., Belshe, R. B., Thumar, B., Casey, R., Newman, F., Polack, F. P., Randolph, V. B., Deatly, A. & other authors (2005). Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. *J Infect Dis* 191, 1093–1104.

Kennedy, H. E., Jones, B. V., Tucker, E. M., Ford, N. J., Clarke, S. W., Furze, J., Thomas, L. H. & Stott, E. J. (1988). Production and characterization of bovine monoclonal antibodies to respiratory syncytial virus. *J Gen Virol* 69, 3023–3032.

Kim, H. W., Canchola, J. G., Brandt, C. D., Pyles, G., Chanock, R. M., Jensen, K. & Parrott, R. H. (1969). Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. *Am J Epidemiol* 89, 422–434.

Kotelkin, A., Prikhod’ko, E. A., Cohen, J. I., Collins, P. L. & Bukreyev, A. (2003). Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. *J Virol* 77, 9156–9172.

Kwong, L. S., Thom, M., Sopp, P., Rocchi, M., Wattegedera, S., Entrican, G. & Hope, J. C. (2010). Production and characterization of two monoclonal antibodies to bovine tumour necrosis factor alpha (TNF-α) and their cross-reactivity with ovine TNF-α. *Vet Immunol Immunopathol* 135, 320–324.

Li, Z., Gabbard, J. D., Mooney, A., Chen, Z., Tompkins, S. M. & He, B. (2013). Efficacy of parainfluenza virus 5 mutants expressing hemaglutinin from H5N1 influenza A virus in mice. *J Virol* 87, 9604–9609.

Lin, Y., Bright, A. C., Rothermel, T. A. & He, B. (2003). Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. *J Virol* 77, 3371–3383.

Meyer, G., Deplanche, M. & Schelcher, F. (2008). Human and bovine respiratory syncytial virus vaccine research and development. *Comp Immunol Microbiol Infect Dis* 31, 191–225.

Nair, H., Nokes, D. J., Gessner, B. D., Dherani, M., Madhi, S. A., Singleton, R. J., O’Brien, K. L., Roca, A., Wright, P. F. & other authors (2010). Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. *Lancet* 375, 1545–1555.

Perez, M., Garcia-Barreno, B., Melero, J. A., Carrasco, L. & Guinea, R. (1997). Membrane permeability changes induced in *Escherichia coli* by the SH protein of human respiratory syncytial virus. *Virology* 235, 342–351.

Polack, F. P., Irusta, P. M., Hoffman, S. J., Schiatti, M. P., Melendi, G. A., Delgado, M. F., Laham, F. R., Thumar, B., Hendry, R. M. & other authors (2005). The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. *Proc Natl Acad Sci U S A* 102, 8996–9001.

Pulmanausahakul, R., Faber, M., Morimoto, K., Spitsin, S., Weihe, E., Hooper, D. C., Schnell, M. J. & Dietzschold, B. (2001). Overexpression of cytochrome c by a recombinant rabies virus attenuates pathogenicity and enhances antiviral immunity. *J Virol* 75, 10800–10807.

Rutigliano, J. A. & Graham, B. S. (2004). Prolonged production of TNF-α exacerbates illness during respiratory syncytial virus infection. *J Immunol* 173, 3408–3417.

Samal, S. K. & Zamora, M. (1991). Nucleotide sequence analysis of a matrix and small hydrophobic protein dicistronic mRNA of bovine respiratory syncytial virus demonstrates extensive sequence divergence of the small hydrophobic protein from that of human respiratory syncytial virus. *J Gen Virol* 72, 1715–1720.

Schmitz, N., Kurrer, M., Bachmann, M. F. & Kopf, M. (2005). Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. *J Virol* 79, 6441–6448.

Schreiber, P., Mattheis, J. P., Dessy, F., Heimann, M., Letesson, J. J., Coppe, P. & Collard, A. (2000). High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian white blue calves previously vaccinated with an inactivated BRSV vaccine. *J Vet Med B Infect Dis Vet Public Health* 47, 535–550.

Segovia, J., Sabbah, A., Mgbebema, V., Tsai, S. Y., Chang, T. H., Berton, M. T., Morris, I. R., Allen, I. C., Ting, J. P. & Bose, S. (2012). TLR2/MyD88/NF-kB pathway, reactive oxygen species, potassium efflux activates NLRP3/ASC inflammasome during respiratory syncytial virus infection. *PLoS ONE* 7, e29695.

Sopp, P. & Howard, C. J. (1997). Cross-reactivity of monoclonal antibodies to defined human leucocyte differentiation antigens with bovine cells. *Vet Immunol Immunopathol* 56, 11–25.

Spann, K. M., Collinds, P. L. & Teng, M. N. (2003). Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. *J Virol* 77, 11201–11211.

Staib, C., Kissing, S., Erflie, V. & Sutter, G. (2005). Inactivation of the viral interleukin 1β receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. *J Gen Virol* 86, 1997–2006.

Stott, E. J. & Taylor, G. (1985). Respiratory syncytial virus. *Arch Virol* 84, 1–52.

Taylor, G., Thomas, L. H., Wyld, S. G., Furze, J., Sopp, P. & Howard, C. J. (1995). Role of T-lymphocyte subsets in recovery from respiratory syncytial virus infection in calves. *J Virol* 69, 6658–6664.

Thomas, L. H., Gourlay, R. N., Stott, E. J., Howard, C. J. & Bridger, J. C. (1982). A search for new microorganisms in calf pneumonia by the inoculation of gnotobiotic calves. *Res Vet Sci* 33, 170–182.
Thomas, L. H., Slott, E. J., Collins, A. P. & Jebbett, J. (1984). Experimental pneumonia in gnotobiotic calves produced by respiratory syncytial virus. *Br J Exp Pathol* **65**, 19–28.

Thomas, P. G., Dash, P., Aldridge, J. R., Jr, Ellebedy, A. H., Reynolds, C., Funk, A. J., Martin, W. J., Lamkanfi, M., Webby, R. J. & other authors (2009). The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. *Immunity* **30**, 566–575.

Triantafilou, K., Kar, S., Vakakis, E., Kotecha, S. & Triantafilou, M. (2013). Human respiratory syncytial virus viroporin SH: a viral recognition pathway used by the host to signal inflammasome activation. *Thorax* **68**, 66–75.

Valarcher, J.-F., Schelcher, F. & Bourhy, H. (2000). Evolution of bovine respiratory syncytial virus. *J Virol* **74**, 10714–10728.

Valarcher, J.-F., Furze, J., Wyld, S., Cook, R., Conzelmann, K.-K. & Taylor, G. (2003). Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. *J Virol* **77**, 8426–8439.

van der Poel, W. H., Schrijver, R. S., Middel, W. G., Kramps, J. A., Brand, A. & Van Oirschot, J. T. (1996). Experimental reproduction of respiratory disease in calves with non-cell-culture-passaged bovine respiratory syncytial virus. *Vet Q* **18**, 81–86.

Viuff, B., Tjernehej, K., Larsen, L. E., Rentved, C. M., Utenthal, A., Rensholt, L. & Alexandersen, S. (2002). Replication and clearance of respiratory syncytial virus: apoptosis is an important pathway of virus clearance after experimental infection with bovine respiratory syncytial virus. *Am J Pathol* **161**, 2195–2207.

Welliver, T. P., Garofalo, R. P., Hosakote, Y., Hintz, K. H., Avendano, L., Sanchez, K., Velozo, L., Jafri, H., Chavez-Bueno, S. & other authors (2007). Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. *J Infect Dis* **195**, 1126–1136.

Werling, D., Collins, R. A., Taylor, G. & Howard, C. J. (2002). Cytokine responses of bovine dendritic cells and T cells following exposure to live or inactivated bovine respiratory syncytial virus. *J Leukoc Biol* **72**, 297–304.

Whitehead, S. S., Bukreyev, A., Teng, M. N., Firestone, C.-Y., St Claire, M., Elkins, W. R., Collins, P. L. & Murphy, B. R. (1999). Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. *J Virol* **73**, 3438–3442.